HSGX vs. INGN, CLGN, COCH, MLSS, RBOT, LFWD, SMTI, ZJYL, BCAB, and CRDF
Should you be buying Histogenics stock or one of its competitors? The main competitors of Histogenics include Inogen (INGN), CollPlant Biotechnologies (CLGN), Envoy Medical (COCH), Milestone Scientific (MLSS), Vicarious Surgical (RBOT), ReWalk Robotics (LFWD), Sanara MedTech (SMTI), Jin Medical International (ZJYL), BioAtla (BCAB), and Cardiff Oncology (CRDF). These companies are all part of the "medical" sector.
Histogenics (NASDAQ:HSGX) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, community ranking, media sentiment and institutional ownership.
Inogen received 27 more outperform votes than Histogenics when rated by MarketBeat users. However, 71.66% of users gave Histogenics an outperform vote while only 70.44% of users gave Inogen an outperform vote.
In the previous week, Inogen had 8 more articles in the media than Histogenics. MarketBeat recorded 8 mentions for Inogen and 0 mentions for Histogenics. Inogen's average media sentiment score of 0.48 beat Histogenics' score of 0.00 indicating that Inogen is being referred to more favorably in the news media.
Histogenics has a beta of 3.1, indicating that its share price is 210% more volatile than the S&P 500. Comparatively, Inogen has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.
40.4% of Histogenics shares are owned by institutional investors. Comparatively, 89.9% of Inogen shares are owned by institutional investors. 19.7% of Histogenics shares are owned by company insiders. Comparatively, 1.0% of Inogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Histogenics has higher earnings, but lower revenue than Inogen. Histogenics is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.
Inogen has a consensus price target of $7.00, indicating a potential downside of 20.81%. Given Inogen's higher possible upside, analysts clearly believe Inogen is more favorable than Histogenics.
Histogenics has a net margin of 0.00% compared to Inogen's net margin of -30.07%. Histogenics' return on equity of -34.96% beat Inogen's return on equity.
Summary
Histogenics and Inogen tied by winning 8 of the 16 factors compared between the two stocks.
Get Histogenics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HSGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Histogenics Competitors List
Related Companies and Tools
